BPC-157 is believed to interact with the nitric oxide (NO) system, angiogenic growth factors, and cellular signaling pathways like FAK-paxillin and VEGF, which are involved in cell migration, cytoskeletal reorganization, and vascular modulation
If that trajectory holds and we need Phase 3 data to confirm we could be looking at the first oral medication capable of delivering weight loss that competes with early injectable results
Once Retatrutide gets an approval, it can be a great addition as a peptide therapy for weight loss
The membrane was then incubated at room temperature in blocking solution for 1 hour, followed by incubation in blocking solution containing the appropriate dilution of either phospho-Jak2 or the primary antibody for growth hormone receptor, for 2 hours
[15] Truong TT, Gardner DK
Possible mild side effects (rare): Temporary nausea or digestive upset